PR86478

HONG KONG, Nov. 9, 2020 /PRNewswire=KYODO JBN/ --

- Introducing a new portfolio of heart valve products aiming to restore health

and extend life

OrbusNeich and P+F today announced they have entered into an agreement for the

exclusive distribution and manufacturing of a range of innovative minimally

invasive heart valve products in the Asia Pacific region, including China, Japan,

Taiwan, South Korea, Hong Kong, Singapore, Malaysia, Australia and New Zealand.

P+F will bring to the partnership a series of innovative minimally invasive

heart valve products premounted on the delivery system using P+F's proprietary

dry valve technology. The product portfolio includes the TricValve(R)

Transcatheter Bicaval Valves and the Vienna Aortic Self-Expandable Transcather

Valve complemented by transcatheter solutions for pulmonary and mitral valve

disease as well as endovascular grafts.

The TricValve(R) Transcatheter Bicaval Valves is a system of two self-expanding

biological valves for the treatment of patients with hemodynamically relevant

tricuspid insufficiency and caval reflux, specifically intended for patients at

extreme risk or who are unsuitable for open heart surgery.

The Vienna Aortic Self-Expandable Transcatheter Valve is designed to treat

severe aortic stenosis in patients at medium to high risk for open heart

surgery. The minimally invasive valve replaces the native aortic valve without

the need for concomitant surgical removal. Both systems are pending CE mark approval.

"We are delighted to collaborate with P+F and to establish a strong presence in

a large and fast-growing transcatheter heart valve market in Asia Pacific. Both

China and Japan face the challenge of a growing elderly patient population with

the prevalence of moderate-to-severe dysfunctional heart valves. Our unique

product line for percutaneous transcatheter based therapeutics will result in

significant improvement of health-related quality of life to our patients,

which is an important measure of procedural success in the elderly," said David

Chien, Chairman, President and CEO, OrbusNeich.

"This joint venture brings us one step closer to providing patients in Asia

Pacific with P+F's transformational heart valve solutions and supports our

strategy of rapid expansion into key, fast-growing markets, globally. It is the

right moment to focus on being the leading player in this region," said

Siegfried Einhellig, President and COO of P+F.

Katharina Kiss, CEO of P+F, commented: "Partnering with OrbusNeich is an ideal

opportunity for us to expand our vision by bringing our innovative heart valves

technology to patients. My mission as a cardiologist is not only to save lives

but to ensure the maximum quality of life for each of our patients and I am

convinced that with the joint efforts of this newly founded Asian joint venture

we will be able to revolutionize the medical landscape."

"This powerful partnership supports our strategic business directive to add

important complementary structural heart devices to our coronary and peripheral

portfolio. We look forward to working with P+F to expand the potential of our

combined strengths in the global medical device business," said Alain Khair,

Senior Vice President and Chief Commercial Officer of OrbusNeich.

About OrbusNeich

OrbusNeich is a global pioneer in the provision of life-changing vascular

solutions and offers an extensive portfolio of products that set industry

benchmarks in vascular intervention. Current products include the world's first

dual therapy stents, the COMBO(R) Plus and COMBO(R) Dual Therapy Stents,

together with coronary stents, speciality balloons, balloons, and microcatheters

marketed under the names of Azule(R), Scoreflex(R), Scoreflex(R) NC, Sapphire(R),

Sapphire(R) II, Sapphire(R) II PRO, Sapphire(R) 3, Sapphire(R) NC, Sapphire(R)

NC Plus, Sapphire(R) II NC, Sapphire(R) NC 24, Teleport(R) and Teleport(R) Control

as well as products to treat peripheral artery disease: the Jade(R) and Scoreflex(R) PTA balloons.

OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China;

Fort Lauderdale, Florida, USA; Hoevelaken, The Netherlands; Zuchwil,

Switzerland; and regional sales offices in Germany, France, Switzerland, Spain,

Japan, Hong, Singapore; and Malaysia. OrbusNeich supplies medical devices to

physicians in more than 60 countries. For more information, visit

www.OrbusNeich.com .

About P+F Products and Features

With more than 25 years of experience in the medical field, the leadership team

of P+F has built a complete infrastructure for research, development,

manufacture, and distribution in order to deliver significant innovations and

add value to its customers and patients. P+F is striving to become the

"standard of comparison" in the development of state-of-the-art innovative

technologies in the field of cardiology products that contribute to human

welfare by the application of biomedical engineering in the research,

development and manufacture of devices which restore health, extend life and

are accessible to all.

The company's lead product, TricValve(R), is currently undergoing the CE

certification process. TricValve(R) is a bicaval, biological, minimally

invasive valves system for the treatment of severe tricuspid insufficiency. The

further pipeline includes biological heart valves like the TAVI system Vienna

Aortic Self-Expandable Transcatheter Valve, a Pulmonary Valve and Mitral Valve

as well as Aortosave(R), a minimally invasive device to treat Type A aortic

dissections, as well as the full portfolio of endovascular grafts. The

proprietary Dry Pericardium technology platform enables off the shelf use of

the company's heart valves.

Headquartered in Vienna, Austria, under the leadership of Prof Dr Katharina

Kiss and Prof Dr Siegfried Einhellig, P+F coordinates worldwide operations. For

more information, visit www.productsandfeatures.com.

Source: OrbusNeich